Teva Pharmaceutical Industries (XTAE:TEVA) EPS (Basic): ₪4.06 (TTM As of Mar. 2026)


XTAE:TEVA Teva Pharmaceutical Industries Ltd XTAE:TEVA
60 GF Score
Price ₪98.39
GF Value ₪61.79
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Teva Pharmaceutical Industries EPS (Basic)?

Teva Pharmaceutical Industries XTAE:TEVA +4.90% 60 EPS (Basic) is ₪4.06 as of Mar. 2026. GuruFocus rates XTAE:TEVA with a GF Score™ of 60/100 and a GF Value™ of ₪61.79 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Teva Pharmaceutical Industries's basic earnings per share (Basic EPS) for the three months ended in Mar. 2026 was ₪0.95. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2026 was ₪4.06.

Teva Pharmaceutical Industries's EPS (Diluted) for the three months ended in Mar. 2026 was ₪0.92. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was ₪3.94.

Teva Pharmaceutical Industries's EPS without NRI for the three months ended in Mar. 2026 was ₪1.57. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was 8.68.

During the past 12 months, Teva Pharmaceutical Industries's average EPS without NRIGrowth Rate was 15.80% per year. During the past 3 years, the average EPS without NRI Growth Rate was 5.20% per year. During the past 5 years, the average EPS without NRI Growth Rate was 1.60% per year. During the past 10 years, the average EPS without NRI Growth Rate was -6.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Teva Pharmaceutical Industries's highest 3-Year average EPS without NRI Growth Rate was 76.90% per year. The lowest was -33.50% per year. And the median was 10.80% per year.

Teva Pharmaceutical Industries  (XTAE:TEVA) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Teva Pharmaceutical Industries EPS (Basic) Related Terms

Teva Pharmaceutical Industries EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Teva Pharmaceutical Industries's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Teva Pharmaceutical Industries EPS (Basic) Chart

Teva Pharmaceutical Industries Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EPS (Basic)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.13 -6.52 -1.48 -4.30 3.65

Teva Pharmaceutical Industries Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.56 0.74 1.13 1.25 0.95
XTAE:TEVA
60GF Score
Teva Pharmaceutical Industries Ltd XTAE:TEVA
EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Teva Pharmaceutical Industries EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Teva Pharmaceutical Industries's Basic EPS for the fiscal year that ended in Dec. 2025 is calculated as

Basic EPS (A: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(4178.831-0)/1145.000
=3.65

Teva Pharmaceutical Industries's Basic EPS for the quarter that ended in Mar. 2026 is calculated as

Basic EPS (Q: Mar. 2026 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(1093.609-0)/1156.000
=0.95

EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₪4.06

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of ₪4.06 mean?
Teva Pharmaceutical Industries (XTAE:TEVA) has a EPS (Basic) of ₪4.06 as of Mar. 2026. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Teva Pharmaceutical Industries and its competitors.
Is Teva Pharmaceutical Industries' EPS (Basic) too high?
Teva Pharmaceutical Industries' current EPS (Basic) is ₪4.06. Overall, Teva Pharmaceutical Industries has a GF Score™ of 60/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Teva Pharmaceutical Industries' EPS (Basic) compare to ZTS and UTHR?
Teva Pharmaceutical Industries' EPS (Basic) of ₪4.06 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Drug Manufacturers company?
A good EPS (Basic) depends on the Drug Manufacturers industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Teva Pharmaceutical Industries and its competitors. Teva Pharmaceutical Industries's current EPS (Basic) is ₪4.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Teva Pharmaceutical Industries stock overvalued right now?
Based on GuruFocus' analysis, Teva Pharmaceutical Industries (XTAE:TEVA) is currently considered Significantly Overvalued. The stock's GF Value™ is ₪61.79, compared to a current price of ₪98.39 — trading 59.2% above its estimated fair value. The current EPS (Basic) is ₪4.06. Teva Pharmaceutical Industries' overall GF Score™ is 60/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Teva Pharmaceutical Industries (XTAE:TEVA), the current EPS (Basic) is ₪4.06 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Teva Pharmaceutical Industries (XTAE:TEVA) Overvalued in 2026?

Based on GuruFocus' analysis, Teva Pharmaceutical Industries stock appears to be overvalued. The current stock price of ₪98.39 is trading 59.2% above its estimated GF Value™ of ₪61.79. GuruFocus considers Teva Pharmaceutical Industries to be Significantly Overvalued.

Key valuation signals for XTAE:TEVA:

  • EPS (Basic): ₪4.06
  • GF Value™: ₪61.79 vs. price of ₪98.39 (59.2% above fair value)
  • GF Score™: 60/100 with 4 warning signs

No single metric tells the full story. See the XTAE:TEVA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Teva Pharmaceutical Industries Business Description

Address 124 Dvora HaNevi’a Street, Tel Aviv, ISR, 6944020
Teva Pharmaceutical, based in Israel, is the world's leading generic drug manufacturer. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in two main therapeutic areas: neurology and immunology. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
60GF Score

Get the complete analysis for XTAE:TEVA

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₪98.39
Price
₪61.79
GF Value